Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Depreciation & Amortization (CF) (2016 - 2025)

Integra Lifesciences Holdings' Depreciation & Amortization (CF) history spans 17 years, with the latest figure at $38.4 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 2.24% year-over-year to $38.4 million; the TTM value through Dec 2025 reached $151.8 million, up 7.76%, while the annual FY2025 figure was $151.8 million, 7.76% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $38.4 million at Integra Lifesciences Holdings, roughly flat from $38.5 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $38.5 million in Q3 2025 and bottomed at $29.2 million in Q1 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $30.8 million (2021), against an average of $32.7 million.
  • The largest annual shift saw Depreciation & Amortization (CF) decreased 4.07% in 2022 before it grew 21.66% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $30.7 million in 2021, then decreased by 4.07% to $29.5 million in 2022, then grew by 5.05% to $31.0 million in 2023, then increased by 21.31% to $37.6 million in 2024, then rose by 2.24% to $38.4 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Depreciation & Amortization (CF) are $38.4 million (Q4 2025), $38.5 million (Q3 2025), and $37.7 million (Q2 2025).